Reported about 1 year ago
Kayyan (1786) benefits from the booming shipment of adhesive gel, with revenue reaching 330 million yuan in the first five months of 2024, a year-on-year increase of 42.1%. The first-quarter net profit after tax reached 51.7 million yuan, a 58% increase compared to the previous year, with EPS at 0.76 yuan. The company's fundamentals are strong, attracting increased buying interest recently. On the 14th, the stock price rose by 6.89% to 124 yuan, crossing the moving average and turning bullish on the KD indicator, with trading volume reaching 2,657 shares. The company is expected to achieve high growth in operations this year, particularly with its main product, the anti-adhesive gel, achieving 100% coverage in Taiwan's medical centers and promising benefits in overseas markets in the third quarter; overseas expansion of subcutaneous fillers and joint cavity injection drugs also shows promise. The self-collagen-proliferating agent (PLLA) has obtained Taiwan's pharmaceutical certification, being the only domestically produced product licensed with the same ingredients as those approved by the U.S. FDA, expected to contribute in the second half of the year.
Source: YAHOO